Payment overview · 2025
General Payments
$328.42
18 reported records · 11 companies
Healthcare provider profile · identity verified
Kasey Danielle Lee, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GLASGOW, KY · NPI 1295345940
Verified facts
What the public records show
CMS Open Payments records show Kasey Danielle Lee, APRN received $328.42 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.07 | 27.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.00 | 16.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.93 | 10.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.80 | 9.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.43 | 7.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $21.09 | 6.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.55 | 5.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.53 | 5.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.21 | 4.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.81 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.00 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.42 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.36 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.71 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.80 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 622 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 93 |
| Lisinopril | Lisinopril | 321 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 62 |
| Omeprazole | Omeprazole | 209 | 55 |
| Gabapentin | Gabapentin | 208 | 42 |
| Metformin Hcl | Metformin Hcl | 204 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 54 |
| Alprazolam | Alprazolam | 175 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 47 |
| Montelukast Sodium | Montelukast Sodium | 139 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 37 |
| Meloxicam | Meloxicam | 128 | 43 |
| Diazepam | Diazepam | 123 | 23 |
| Prednisone | Prednisone | 120 | 93 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 22 |
| Trazodone Hcl | Trazodone Hcl | 115 | 26 |
| Furosemide | Furosemide | 108 | 34 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 105 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 27 |
| Simvastatin | Simvastatin | 92 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 21 |
| Clonazepam | Clonazepam | 81 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 61 |
| Glipizide | Glipizide | 75 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 21 |
| Jardiance | Empagliflozin | 71 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Losartan Potassium | Losartan Potassium | 67 | 21 |
| Atenolol | Atenolol | 61 | 20 |
| Allopurinol | Allopurinol | 59 | 13 |
| Potassium Chloride | Potassium Chloride | 58 | 19 |
| Fluconazole | Fluconazole | 56 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 16 |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 11 |
| Ozempic | Semaglutide | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 44 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Azithromycin | Azithromycin | 37 | 35 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 27 |
| Cephalexin | Cephalexin | 34 | 24 |
| Famotidine | Famotidine | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Nystatin | Nystatin | 18 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.42 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FANAPT, Flector, JOURNAVX, Licart, NURTEC ODT, Ohtuvayre, QULIPTA, TRINTELLIX, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trintellix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error